



PUBLIC DISCLOSURE SYNOPSIS

Project Number:	GLPG3067
Study Number:	GLPG3067-CL-202
Study Title:	A Phase II, randomized, double-blind, placebo-controlled, multi-center study to evaluate the efficacy, safety, tolerability and pharmacokinetics of orally administered combination of GLPG3067, GLPG2222 and GLPG2737, in adult subjects with cystic fibrosis homozygous or heterozygous for F508del CFTR
EudraCT Number:	2018-000098-61
ClinicalTrials.gov Identifier:	N/A
Study Initiation and Final Completion Date:	Data not available. This study was cancelled prior to enrollment of any study subjects and therefore no data was collected.
Development Phase:	2
Sponsor:	Galapagos NV Generaal De Wittelaan L11 A3 2800 Mechelen, Belgium
Status:	Final
Version:	1.0
Date:	29-Sep-2020

Confidentiality Statement

The information contained in this document is privileged and confidential. It is the property of Galapagos NV and may not be used, disclosed, reproduced or otherwise disseminated within your organization or communicated to any third parties without the express written authorization of Galapagos NV.

1. STUDY OBJECTIVE

Data not available

2. METHODS

Data not available

3. RESULTS

3.1. Subject disposition and demography

Data not available

4. EFFICACY RESULTS

Data not available

5. SAFETY RESULTS

Data not available

6. CONCLUSIONS

Data not available

This study was cancelled prior to enrollment of any study subjects and therefore no data was collected.